Latest News by Industry
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nov 25, 2022--
Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108 th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm ® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.
“As the global leader in breast imaging, we are committed to addressing the unmet needs of physicians and their patients across the continuum of breast care and we’re eager to engage with industry leaders at this year’s RSNA meeting to share our vision for the future of breast health,” said Erik Anderson, President of Hologic’s Breast and Skeletal Health Solutions Division. “We are equally excited to showcase our new Affirm Contrast Biopsy technology, which is a great example of our commitment to physicians and patients in action.”
Affirm Contrast Biopsy software allows clinicians to target and acquire tissue samples in lesions identified with I-View ® Contrast-Enhanced Mammography software. The contrast solution provides healthcare facilities with a viable and attractive alternative to breast MRI, which historically has been used to find and biopsy more elusive lesions, such as those that cannot be seen via mammography or ultrasound. While breast MRI can be time-consuming and costly, contrast technology gives radiologists another option in the mammography suite that addresses these shortcomings. 1,2 In a recent clinical study, 98% of patients had an overall positive opinion of their procedure experience with Affirm Contrast Biopsy software. 3
RSNA attendees can experience Hologic’s portfolio at Booth 1911 in South Hall Level 3 at McCormick Place in Chicago. In addition to the Affirm Contrast Biopsy software, Hologic will feature its Dimensions ® mammography portfolio and Supersonic® MACH™ ultrasound systems.
Hologic will also host a series of CME- and non-CME-accredited medical education symposiums and learning opportunities, accessible to attendees on-site and from remote locations. The medical education sessions include:
About Hologic, Inc.
Hologic, Inc. is a global medical technology innovator primarily focused on improving women’s health and well-being through early detection and treatment. Its advancements include invention of the world’s first commercial 3D Mammography™ system to fight breast cancer; leadership in testing for cervical cancer, sexually transmitted infections, respiratory illnesses and the virus that causes COVID-19; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.
The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women. hologic.com
Hologic, 3D Mammography, 3Dimensions, Affirm, Brevera, Dimensions, Genius AI, I-View, Mach, Selenia, ShearWave, Supersonic, and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.
| ____________________ | ||
1 | Publication for reference: Kaur, Piccolo, Arasaratnam. Implementation of Contrast-Enhanced Mammography in Clinical Practice, chapter 7, Nori, Kaur (eds .), Contrast-Enhanced Digital Mammography (CEDM). Springer, 2018. | |
2 | Hobbs MM, Taylor DB, Buzynski S, and Peake RE. Contrast-enhanced spectral mammography (CESM) and contrast MRI (CEMRI): Patient preferences and tolerance. Journal of Medical Imaging and Radiation Oncology. 2015;59:300-305 | |
3 | Hologic clinical study CSR-00266 Rev 001 2022 |
Source: Hologic, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221125005011/en/
CONTACT: Media Contact:
Jane Mazur
Vice President, Corporate Communications
(+1) 508.263.8764
jane.mazur@hologic.com
Investor Contact:
Ryan Simon
Vice President, Investor Relations
(+1) 858.410.8514
ryan.simon@hologic.com
KEYWORD: ILLINOIS MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SOFTWARE OTHER HEALTH RADIOLOGY ONCOLOGY CONSUMER TECHNOLOGY MEDICAL DEVICES ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY SURGERY BIOTECHNOLOGY WOMEN HEALTH
SOURCE: Hologic, Inc.
Copyright Business Wire 2022.
PUB: 11/25/2022 08:08 AM/DISC: 11/25/2022 08:08 AM
http://www.businesswire.com/news/home/20221125005011/en